Report Detail
Purchase Price: $4,750.00
Microinvasive Glaucoma Surgery (MIGS) Devices
Glaucoma is the second leading cause of blindness worldwide following cataracts, and the leading cause of irreversible blindness. According to the World Health Organization (WHO), nearly 80 million people are living with glaucoma worldwide.
Glaucoma is a group of eye disorders characterized by progressive damage to the optic nerve and loss of nerve tissue associated with elevated intraocular pressure (IOP) due to the inadequate drainage of fluid in the eye. There are several types of glaucoma, but the most common form is primary open-angle glaucoma (POAG), in which the drainage angle formed by the iris and cornea remains open but other parts of the drainage system fail to drain properly.
Glaucoma cannot be prevented, but it can be controlled if diagnosed and treated early with topical eye medication or surgery. Vision loss due to glaucoma cannot be restored, and if a patient is diagnosed with glaucoma, they will require monitoring the rest of their life.
Minimally invasive glaucoma surgery – commonly termed microinvasive glaucoma surgery (MIGS) – is a new and promising type of glaucoma surgery that is experiencing rapid adoption due to its ability to provide an effective surgical alternative to selected patients with fewer surgical risks. MIGS utilizes tiny, microsurgical instruments and devices and smaller incisions that result in less risk of tissue trauma and complications than conventional glaucoma surgery to improve fluid drainage and reduce IOP.
Global sales of MIGS devices totaled an estimated $488.1m in 2022. Market drivers include: the increasing prevalence of glaucoma, strong medical necessity in preventing blindness, strong benefits (e.g., ability to lower IOP by 20% or more and lower dependency on burdensome topical medications or riskier glaucoma surgery), technological advancements improving safety and efficacy, solid clinical profile (to date), and growing surgeon network. Limiters to the market include: macroeconomic factors, high surgical cost, reimbursement issues (e.g., recent Medicare rate reductions/coverage questions), steep surgeon learning curve, limited access to MIGS in emerging regions, need for frequent follow-up or additional surgeries, lack of long-term clinical trials assessing durability and technique comparisons.
This analysis includes a discussion of products, current revenues and forecast markets, competitors, and opportunities in the global market for MIGS devices; revenues include sales of MIGS devices and associated surgical products, including implants/microstents, surgical instruments, and disposables/consumables. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2022–27.
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
Related Medtech Insight articles:
Subscribe to Medtech Insight to view these articles and more!
